SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is capturing significant community attention as investors rally around its AI-driven infrastructure and potential for long-term utility within the Base ecosystem. Bullish sentiment is being fueled by viral discussions linking the project to high-profile AI developments, prompting active accumulation as holders look toward future growth phases.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health is trending as institutional interest builds around its Ophthalmic platform and the favorable formulary status of VEVYE, leading to strong community conviction that the company is at a historic inflection point. Investors are closely monitoring record prescription growth and sales force expansion as primary catalysts to drive the stock toward long-term targets.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is seeing a surge in investor interest driven by a significant expansion of its NFL live sports content and the broadening of its ad-supported tier to new global markets. Community members are actively debating the timing of share buybacks and whether this recent price action represents a sustainable reversal or merely a temporary relief rally.

Canary XRP ETF - Common Shares of Beneficial Interest

Canary XRP ETF

The XRP ecosystem is experiencing a surge in activity driven by optimism surrounding the CLARITY Act and significant institutional interest in spot ETFs. Investors are actively discussing the potential for increased liquidity, the role of XRP in bridging traditional and digital finance, and the impact of sustained ETF inflows on market supply.

Volatility Shares Trust - Volatility Shares Trust XRP ETF

XRP ETF

The community is heavily focused on XRP following progress with the CLARITY Act, which seeks to clarify the asset's regulatory status as a digital commodity. Investors are actively discussing the potential impact of this legislative momentum, alongside institutional integration news and the growth of XRP-linked exchange-traded products.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

XRP is trending as investors digest the advancement of the CLARITY Act, which seeks to clarify the digital asset's regulatory status, while enthusiasm grows around the increasing institutional adoption fueled by the Bitwise XRP ETF and Ripple's expanding payment infrastructure. Community discussions are heavily focused on navigating current market volatility, analyzing long-term utility for cross-border settlements, and debating the potential impact of legislative developments on future price momentum.

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

The community is actively debating the legitimacy of trending SpaceX-related tickers and crypto tokens, with many users warning that these assets are scams or unauthorized proxies capitalizing on persistent IPO rumors. Investors are expressing a mix of skepticism toward potential rug pulls and excitement over legitimate aerospace sector opportunities, while discussing the impact a future SpaceX public offering could have on the broader market.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is experiencing significant momentum as investors rotate capital into decentralized AI infrastructure, driven by institutional partnerships and a broader market focus on autonomous agent technology. The community is actively debating the project's long-term utility against market volatility, with many users focused on identifying accumulation points while weighing the potential for a larger breakout within the AI crypto narrative.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is seeing heightened market volatility and active community debate following multiple FDA rejections of its skin cancer drug, RP1. Investors are intensely focused on recent leadership changes at the agency and conflicting narratives regarding the drug's regulatory path, leading to speculative trading and heated discussions over the company's future viability.

monday.com Ltd. engages in the business of operating a cloud-based visual work operating system that consists of modular building blocks that can be easily used and assembled to create software applications and work management tools and serves as a connective layer to integrate with various digital tools across an organization. It operates through the following geographical segments: United States, EMEA, United Kingdom, and Rest of the World. The company was founded by Roy Mann, Eran Kampf, and Eran Zinman in 2012 and is headquartered in Tel Aviv, Israel.

Monday.Com Ltd

Monday.com Ltd

Monday.com is facing significant downward pressure as investors rotate out of SaaS stocks amid broader concerns that AI agents could disrupt the sector's traditional business models. Despite strong earnings performance and a robust cash position, the community is actively debating whether the recent sell-off is an overreaction to AI-driven fear or a justified repricing due to slowing growth and aggressive competition.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What's Behind The Rise In Artelo Biosciences Stock?

Artelo Biosciences, Inc. (NASDAQ:ARTL) shares jumped on Monday after the company announced the publication of a peerreviewed article highlighting FABP5 as a therapeutic target for pain.read more...

Rogan’s Runners Market Ignites

The market is feeling the effect of Joe Rogan getting in President Trump’s ear and psychedelic therapeutics gaining regulatory tailwinds. Meanwhile, adjacent sectors are quietly building foundational breakthroughs. Wearables are evolving into neural interfaces, biomaterials are transitioning from lab curiosity to production reality, and oncology platforms continue their grind through clinical validation. $KBLB, $WLDS, $ARTL, $ENVB, $TOVX, $PBM, $CMND, $CMPS, $HELP,

<ul class="summary-bullets"><li>Artelo CEO Gregory D. Gorgas on Tuesday stated that the interim data in the Phase 2 trial of ART27.13 is encouraging.</li><li>Artelo added that ART27.13 is currently under investigation as an orally administered agent for the treatment of glaucoma in an externally funded Phase 2 study.</li><li>The company is also developing ART27.13 as a potential companion therapy to preserve muscle in patients undertaking GLP-1 treatment.</li></ul>Artelo Biosciences Inc. (ARTL) shares soared more than 21% in Tuesday’s pre-market trade&nbsp;before losing most of the gains to hover about 4% higher in the day’s opening trade after the company announced that it has regained compliance with Nasdaq’s listing requirements.Artelo stated that the Nasdaq sent a letter confirming the company is in compliance with the exchange’s rule requiring a minimum of $2.5 million in stockholders’ equity and another rule requiring an annual shareholders’ meeting.The company stated that, in accordance with Nasdaq’s listing rules, Artelo will be subject to a mandatory panel monitor for a period of one year from the date of this letter.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ARTL">Artelo Biosciences</a> trended in the ‘bearish’ territory at the time of writing.<h2 class="st-heading-2">Artelo CEO Says ART27.13 Interim Data Is Encouraging</h2>Artelo CEO Gregory D. Gorgas stated on Tuesday that the interim data from the Phase 2 trial of ART27.13 is encouraging.“With this matter behind us, we remain focused on disciplined execution across our portfolio, including progressing potential partnership negotiations with ART27.13 boosted by the encouraging Phase 2 CAReS interim data suggesting its potential for mitigating or reversing the effects of cancer anorexia-cachexia syndrome,” he said.Artelo added that ART27.13 is currently under investigation as an orally administered agent for the treatment of glaucoma in an externally funded Phase 2 study.<h2 class="st-heading-2">Artelo Expands ART27.13’s Development</h2>The company announced last month that it had expanded development of ART27.13 as a potential companion therapy to preserve muscle in patients undergoing glucagon-like peptide-1 (GLP-1) receptor agonist therapy.Artelo cited observations among patients with cancer anorexia and cachexia showing improvements in lean body mass and physical activity during ART27.13’s Phase 2 trial.The company also closed an $11 million private placement of 3.2 million shares last week, which it intends to use toward the repayment of certain bridge debt and to meet other working capital requirements.<a href="https://stocktwits.com/symbol/ARTL">ARTL stock</a> is up 84% year-to-date, but down 58% over the past 12 months. The Vanguard Extended Market Index Fund ETF (VXF) is up 35% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-fall-ongoing-us-strikes-iran-trump-tuesday-deadline/cZJJpRQRIpL">Dow Futures Fall Over 200 Points Amid Ongoing US Strikes Against Iran, While Trump’s Tuesday Deadline Draws Closer</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Artelo Biosciences logo is seen displayed on a smartphone screen.

Why Is ARTL Stock Soaring Today?

Artelo stated that the Nasdaq sent a letter confirming the company is in compliance with the exchange’s rule requiring a minimum of $2.5 million in stockholders’ equity and another rule requiring an annual shareholders’ meeting.

Equity

<ul class="summary-bullets"><li>Artelo Biosciences shares gained more than 23% before the opening bell on Tuesday after the company announced the closure of its $11 million private placement of common stock.</li><li>Bullfrog AI shares soared more than 12% in Tuesday’s pre-market trade, building on the gains of 107% on Monday after the company announced an agreement with a major global pharmaceutical company.</li><li>Hitek Global shares more than doubled in Tuesday’s pre-market trade, soaring 110% as the company’s $3 million registered direct offering of Class A ordinary shares closed on Monday.</li></ul>U.S. equities were in the green in Tuesday’s pre-market trade after President Donald Trump reportedly indicated that he would be willing to end the Iran war without a complete reopening of the Strait of Hormuz.According to a report by The Wall Street Journal, President Trump told his aides about his willingness to end the war without getting Iran to reopen the strait following an assessment that this mission would result in prolonging the conflict beyond the four to six-week timeline.At the time of writing, the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which tracks the S&amp;P 500 index, was up 0.92%; the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust ETF</a> (QQQ) rose 0.86%; and the&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA) gained 0.94%. Retail sentiment on Stocktwits regarding the S&amp;P 500 ETF was in the ‘extremely bearish’ territory.<h2 class="st-heading-2">Here are the top stocks making the biggest moves in Tuesday’s pre-market trade:</h2><a href="https://stocktwits.com/symbol/ARTL">Artelo Biosciences Inc. (ARTL)</a>Artelo Biosciences shares gained more than 23% before the opening bell on Tuesday after the company announced the closure of its $11 million private placement of common stock. Artelo stated that it intends to use the proceeds to repay a bridge debt and meet working capital requirements.<a href="https://stocktwits.com/symbol/ARTL">ARTL stock</a> is up 139% year-to-date.<a href="https://stocktwits.com/symbol/BFRG">Bullfrog AI Holdings Inc. (BFRG)</a>Bullfrog AI shares soared more than 12% in Tuesday’s pre-market trade, building on the gains of 107% on Monday after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bfrg-stock-more-than-doubled-today-what-is-fueling-the-surge/cZERFnXRIZz">announced</a> an agreement with a major global pharmaceutical company to accelerate its drug discovery and clinical development programs.<a href="https://stocktwits.com/symbol/BFRG">BFRG stock</a> is up 19% year-to-date.<a href="https://stocktwits.com/symbol/HKIT">Hitek Global Inc. (HKIT)</a>Hitek Global shares more than doubled in Tuesday’s pre-market trade, soaring 110% as the company’s $3 million registered direct offering of Class A ordinary shares closed on Monday.<a href="https://stocktwits.com/symbol/HKIT">HKIT stock</a> is down 98% year to date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/jerome-powell-fed-iran-war-effects-not-facing-policy-decision-yet/cZERs6iRIN9">Powell Says Fed ‘Not Really Facing’ Policy Decision Yet Amid Iran Oil Shock – Adds Central Bank Will Be ‘Mindful Of The Broader Context’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ARTL, BFRG, HKIT Among Stocks Soaring Before The Bell — Top Pre-Market Gainers Today

U.S. equities gained in Tuesday’s pre-market trade after President Donald Trump reportedly stated that the Iran war could be ended without a full reopening of the Strait of Hormuz.

Medical Stocks To Research - March 27th

UnitedHealth Group, Artelo Biosciences, and Eli Lilly and Company are the three Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly...

Artelo Biosciences Stock Skyrockets 205%

(RTTNews) - Shares of Artelo Biosciences, Inc. (ARTL) are skyrocketing about 205 percent on Friday morning trading despite no corporate-related announcements to influence the movement...

AI, Biotech, and Biologics Drive Big Narratives

A new wave of healthcare innovation, powered by artificial intelligence, next-generation biologics, and shifting regulatory pathways, is colliding with market dynamics to create both breakthrough potential and high-volatility trading setups. $ARTL, $TGNT, $ADMA, $RCKT, $LTRN, $GCTK

Artelo Biosciences Targets GLP-1 Boom with Muscle Preservation Strategy as Stock Eyes Squeeze Potential

Artelo Biosciences (NASDAQ:ARTL) is expanding the development pathway for its lead candidate ART27.13, positioning the compound as a potential companion therapy to GLP-1 weight-loss drugs, one of the fastest-growing segments in biopharma.

<ul><li>Artelo indicated it will defer the planned securities offering for the moment.</li><li>The company confirmed no shares were sold and may consider fundraising later.</li><li>On Thursday, Artelo said it plans to test ART27.13 for preserving muscle in GLP-1 patients.</li></ul>Artelo Biosciences, Inc. (ARTL)&nbsp; has formally requested the withdrawal of its recently effective registration statement for a planned securities offering, signaling a pause in its capital-raising efforts.On Friday, the company submitted a request under Rule 477 of the Securities Act of 1933 to withdraw its Form S-1, initially filed with the U.S. Securities and Exchange Commission on March 20 and declared effective on March 25.<h2 class="st-heading-2">Artelo Pauses Proposed Securities Offering</h2>Artelo stated that it does not plan to move forward with the proposed securities offering at this time.&nbsp;The company emphasized that no shares were issued or sold under the registration statement, and it intends to revisit capital-raising options in the future when conditions are more favorable.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/ARTL">Artelo Biosciences stock</a> traded over 420% higher on Friday afternoon.&nbsp;On Stocktwits, retail sentiment around the stock changed to ‘extremely bullish’ from ‘bullish’ territory the previous day amid ‘extremely high’ message volume levels.&nbsp;Additionally, the company announced a new private placement involving the sale of more than 3.18 million shares or equivalent pre-funded warrants. The transaction is expected to finalize around March 30, and the company expects gross proceeds of approximately $11 million.<h2 class="st-heading-2">Strategic Expansion Initiative</h2>On Thursday, Artelo announced plans to explore a new application for its ART27.13 compound. The therapy targets muscle preservation in patients undergoing glucagon-like peptide-1 (GLP-1) receptor agonist treatment to address lean body mass loss.&nbsp;The initiative builds on multiple promising developments. ART27.13 demonstrated protective effects on muscle in the CAReS trial, showing increased lean body mass and enhanced physical activity in cancer anorexia and cachexia patients.Artelo Biosciences is a clinical-stage pharmaceutical company focused on treatments for cancer, pain, dermatologic, and neurological conditions.ARTL stock has gained over 170% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/entergy-meta-ink-agreement-to-fund-new-gas-plants-for-louisiana-ai-data-center/cZ3H5r4RImT">Entergy, Meta Ink Agreement To Fund New Gas Plants For Louisiana AI Data Center</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 Why Did ARTL Stock Skyrocket Over 420% Today? 

Artelo requested withdrawal of its Form S-1, effective March 25, and will not proceed with the planned securities offering.

Small Cap Stocks To Watch Now - March 18th

AltC Acquisition, Direxion Daily MU Bull 2X Shares, and Artelo Biosciences are the three Small Cap stocks to watch today, according to MarketBeat's stock screener tool. Small-cap stocks are shares of...

Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.

ARTL
Artelo Biosciences Inc

Feed

News

Sentiment

Fundamentals

Info

Compact View

Latest ARTL News

ARTLArtelo Biosciences Inc